



February 12, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Investor Presentation - Q3 FY26 Results

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose a copy of the Investor Presentation on the Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2025.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442


info@lupin.com | www.lupin.com



Investor Presentation

Q3 FY26

February 12, 2026



Safe Harbor Statement



Materials and information provided during this presentation may contain forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

Risks and uncertainties include general industry, geopolitical and market conditions, domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related forward looking statements. Product risks and uncertainties include, but are not limited to, technological advances, regulatory environment and patents obtained by other pharmaceutical companies. Challenges inherent in new product development include but are not limited to completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and international operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. You are cautioned not to place undue reliance on these forward- looking statements, which reflect our opinions only as of the date of the presentation.

Lupin Limited, its directors, officers, employees and affiliates expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.



Q3 FY26 Performance



Q3 FY26 – Key Growth Metrics

Continued Strong Operating Performance



Key Metrics



71,005 mn Sales

↑ 26% YoY



22,095 mn EBITDA¹

↑ 62% YoY

**31.1%
Margin**



11,756 mn Net Income²

↑ 38% YoY

**16.6%
Margin**

Business Performance

Values in INR unless indicated otherwise



India

20,387 mn | ↑ 6% YoY



APAC

2,949 mn | ↑ 14% YoY



LATAM

3,267 mn | ↑ 70% YoY



ROW

2,959 mn | ↑ 47% YoY



North America

32,183 mn | ↑ 52% YoY



EMEA

7,066 mn | ↑ 13% YoY



API

2,195 mn | ↓ 24% YoY

1. EBITDA margin excludes Forex and Other Income on Net Sales as base; Arrows indicate Growth / degrowth

2. Net income is after adjusting NCI stake from PAT




Q3 FY26 – Key Developments

Consistent improvement in margins



Financials



*excludes Other Operating Income

** EBITDA margins exclude Fx and Other Income on Net Sales as base

Committee for Medicinal Products for Human Use (CHMP)

Key Launches / Approvals

**gRisperdal Consta®
Injection &
gRavicti® (AG)**

Launched
In US

**Pegfilgrastim
(Armlupeg™)
biosimilar**

US FDA
approval

Business Development

- Exclusive US partnership with Valorum Biologics for Armlupeg™ biosimilar (pegfilgrastim-unne)
- Exclusive partnership with Gan & Lee (China) for Bofanglutide, a novel fortnightly GLP-1, for Indian market
- Strategic Alliance with PolyPeptide Group AG in CDMO business to scale Global Peptide Supply Chain

Compliance

US FDA


- Nagpur Unit-I: NAI with Zero observations & Nagpur Unit-II (injectable): VAI (EIR received)
- Aurangabad: VAI (EIR received); Pune Biotech: BLA approved
- Goa & Somerset: response submitted

Others

- Aurangabad: ANVISA Brazil (no observation)
- Tarapur: State FDA & CDSCO approval received
- Positive CHMP# opinion of EMA recommending marketing authorization for Ranibizumab

Q3 FY26: Financial Snapshot

Sales Mix



Key Financials

INR mn

	Q3 FY26	Q3FY25	Q2 FY26
Sales	71,005	56,186	68,314
EBITDA ³	22,095	13,659	21,376
Net Income ⁴	11,756	8,552	14,779

1. United States sales includes IP income

2. Other Developed Markets comprises of Canada, Australia, Europe and others; Emerging Markets comprises of LATAM, South Africa, Philippines & RoW


3. EBITDA excludes Fx and Other income

4. Net income is after adjusting NCI stake from PAT

India: Focus on outperforming market growth

India business grew 5.6%¹ YoY

India Sales (INR mn)



Outperformance in Key Therapeutic Segments

- India Rx business grew by 10.9%¹ in Q3FY26 (9.4%¹ in 9MFY26 vs IPM growth of 9.3%²)
- Key segments – Cardiology(1.3x), Respiratory (1.6x), GI (1.6x) & Pain (1.2x) grew faster than market during 9MFY26^{1,2}
- Anti-diabetes segment grew 8.8%¹ vs IPM growth of 15.6%² impacted by LOE in IL portfolio during Q3FY26
- In-licensed % of India Rx sales¹: 6% in 9MFY26; ~12% for FY25

Leveraging Chronic Leadership

#2

Rank
Respiratory²



#3

Rank
Diabetes Care²



#3

Rank
Cardiac²



- Chronic growth 13% in 9MFY26 vs IPM growth of 12%²; Chronic share¹ ~67% in Q3FY26 vs ~64% in FY25
- Volume growth of 5.6% in 9MFY26¹
- Total sales force ~11,400 (includes total MRs ~8,900)

Healthy Pipeline of launches in FY26



4 in
Respiratory



2 in
Urology



3 in
CNS



1 in
Oncology



1 in
Diabetes



1 in
Derma



1 in
Cardiac

- Umetrio® Ranked #2 new launch in respiratory³
- Launched Two New divisions including 1 in Obesity
- Launched 13 Products in 9MFY26

India: Amplifying our Core

IRF poised to outperform IPM by 1.2–1.3x with key drivers in place



Enhancing penetration and reach

- Maximizing Chronic focus with ~70% share by FY30
- Expansion of Gastro Task Force & launch of Nebulization Task Force to strengthen the respiratory portfolio
- Build emerging therapies
- Target Alliances/M&A/inorganic activities – mid size companies, brands & portfolios



Innovative Product Pipeline

- In-house pipeline of innovative assets & biosimilars
- In-license new products via partnerships including GLP-1s



Expanding footprint

- Partnering in e-commerce, organized retail and institutional business
- Expansion of Extra-Urban division (Uday)
- Strategic expansion planned in hospital channel

Enabling end to end healthcare ecosystem and access for the patient

Business Verticals



CHC Portfolio catering to GI, VMS, Cough/cold therapies



Diagnostics platform expanding across India



Beyond the pill approach with digital offering for cardiac patients and Neuro-rehab



Empowering community



Building capacity of HCPs and empowering patients by improving awareness and adherence through PSPs¹



Enhance market reach of generics business by collaborations with retailers and channel partners



United States: Continued momentum on Key Launches

Leadership: 4.8% Gx TRx volume share in U.S.¹



**#3
in the US¹**

Maintaining
leadership



**#1
in 55 products²**

Top 3 in 116
products²

Growing Respiratory Portfolio



**~32%
Tiotropium**

Gx market share²



**~12%
Arfomoterol**

Brand + Gx market
share²



**~16%
Albuterol**

Gx market share²

Consistent Sales trajectory³


Sales in US\$ Mn



46% YoY



11% QoQ



Key Highlights

- Highest quarterly sales recorded
- Growth driven by both NPLs & base business offset by additional Gx competition in base business
- Successful launch of Risperidone Inj. (gRisperdal Consta®)
- US FDA approval for biosimilar Armlupeg™ (pegfilgrastim-unne) injection

Continued momentum led by investments in complex Gx & 505(b)(2)

- Plans to file 10-15 ANDAs in FY26 including two 505(b)(2)s
- 52 FTFs incl. 22 exclusive FTFs
- Strong pipeline of 45+ Injectables and 20+ inhalation
 - Target of 100+ NPLs; ~65%+ share of NPL⁴ Revenue from Complex Products by FY31
- Building on Specialty aspiration
 - Xopenex, NaMuscla
 - M&A & Partnerships to grow portfolio

Continued cost optimization initiatives to improve profitability

R&D pivoting towards complex generics and biosimilars

Substantial Capabilities to become CGx powerhouse

- **Inhalation:** Global presence with end-to-end capabilities of MDIs, DPIs, Soft-Mist Inhalers, Nasal Sprays and Nebules
- **Injectables:** Robust pipeline of peptide, iron colloid, depot, liposomal and 505(b)(2) injectable products in development
- **Biosimilars:** A fully vertically-integrated commercial-stage company with regulated market approvals and launches

Long term Goals

Complex Generics: Launches in Regulated Markets by 2028

- 20 complex product launches in the areas of inhalation, injectables, Ophthalmics

Biosimilar and Novel Complex Products: By 2028

- Complete 3 biosimilar filings in regulated markets
- Launch 10 novel complex pipeline products in India

Achieve Best-in-Class Quality

Recent Track Record

Successful outcomes in last 12 months

- Successful completion of FDA inspections for Pune Biotech (BLA received), Nagpur Unit-II (Injectable - VAI, EIR received)
- EIR received for Nagpur Unit-I (NAI), Pithampur Unit-III (VAI) & Aurangabad (VAI); Response submitted for Somerset and Goa




3 Remediation sites:

- Tarapur, Mandideep Unit-1 & Pithampur Unit-II

Our Quality Goals

- Regulatory Compliance: Target all sites to have satisfactory compliance status
- Conduct Quality Audits of suppliers regularly and provide mandatory cGMP Training to all relevant employees

Key Financial Metrics: Quarterly Trend





P&L Highlights Q3 FY26

Particulars	Q3'FY26	% of Sales	Q3'FY25	% of Sales	YoY Growth	Q2'FY26	% of Sales	QoQ Growth
Net Sales	71,005	100.00%	56,186	100.00%	26.4%	68,314	100.00%	3.9%
Other operating income	670	0.9%	1,492	2.7%	(55.1%)	2,161	3.2%	-69.0%
Total revenue	71,675	100.9%	57,678	102.7%	24.3%	70,475	103.2%	1.7%
Gross Profit (excl. other operating income)	52,224	73.5%	38,970	69.4%	34.0%	50,066	73.3%	4.3%
EBITDA¹	22,095	31.1%	13,659	24.3%	61.8%	21,376	31.3%	3.4%
Net Income²	11,756	16.6%	8,552	15.2%	37.5%	14,779	21.6%	(20.5%)

1. EBITDA excludes Fx and Other income. EBITDA margins is calculated as EBITDA on Net Sales as base

2. Net income is after adjusting NCI stake from PAT | Net income for Q3FY26 includes net one-time exceptional items of INR 4,266 Mn



P&L Highlights 9M FY26

Particulars	9M'FY26	% of Sales	9M'FY25	% of Sales	YoY Growth
Net Sales	200,956	100.0%	166,299	100.0%	20.8%
Other operating income	3,877	1.9%	4,109	2.5%	(5.6%)
Total revenue	204,834	101.9%	170,408	102.5%	20.2%
Gross Profit (excl. other operating income)	146,208	72.8%	114,739	69.0%	27.4%
EBITDA¹	59,885	29.8%	39,854	24.0%	50.3%
Net Income²	38,725	19.3%	25,091	15.1%	54.3%

1. EBITDA excludes Fx and Other income. EBITDA margins is calculated as EBITDA on Net Sales as base

2. Net income is after adjusting NCI stake from PAT | Net income for 9MFY26 includes net one-time exceptional items of INR 4,266 Mn in Q3FY26



Lupin at a Glance

Global Presence



14th



\$2.7 Bn

Largest Generic Company (by sales¹)

Annual sales in FY25⁶



24,000+ Lupinytts



\$624 Mn

Reaching lives in 100+ countries

EBITDA in FY25⁶

Local Leadership

3rd

Largest In the US (by prescriptions²)

8th

India Pharma Market Rank (by sales³)

4th

Largest Australia Gx (by sales⁴)

7th

Largest South Africa Gx (by sales⁵)



Strong R&D Focus

453

ANDAs and NDAs filed with U.S. FDA⁷

157

US DMF Filings⁷

848

Active Patents Applications⁷

Geographically Diverse

India

75,773

34%

United States

79,975

36%

API
11,772
5%

Emerging Markets⁸
25,354
11%

Other Developed Markets⁸
29,047
13%

in INR Mn
As of FY25 Values

Growing Sustainability

S&P Global

91/100

Achieved new benchmark in S&P Global ESG Rating 2025. Cementing sustainability leadership position in global pharma industry⁹

Catalyzing Treatments that serve Patients around the world



United States

Evolving portfolio and pipeline in Complex platforms (Inhalation, Biosimilars and Injectables) and Specialty.

Scaled product platforms in oral, ophthalmic and dermatology.



Other Developed Markets

Driving operating leverage in Portfolio, Capex and R&D across Platforms through markets with similar regulatory regimes (US, UK, Europe, Canada and Australia).



India

Delivering above-market growth.

Innovative brands through organic and in-organic means (licensing, partnering, and acquisitions).

Strategic adjacencies.



Other Emerging Markets

Global reach and scale positions us as a partner of choice in South Africa, Brazil, Mexico, Philippines and Southeast Asia.

Leading Partner for Global Institutions on TB care.



API

Substantial scale achieving reliability of supply, cost position to serve internal as well as external customers and contribute meaningfully to Global Public Health.

Best in Class Global Quality

Continuous Improvement Culture



Lupin's ESG Update

Paving a sustainable future for Planet, People and Patients



	ESG Goal	Status FY 2025
 Climate Change¹	38% GHG Reduction by 2030	26% GHG Reduction
 Water	50% Recycling by 2030	44% Recycling
 Biodiversity Assessment	100% Global Sites by 2030	6 Sites Completed
 Diversity	15% Women by 2030	9% Women
 Employee Volunteering	50,000 hours by 2030	24,000+ hours
 Supplier Assessment²	100% Suppliers by 3- year cycle	Goal Achieved for FY25 cycle
 Education & Awareness	3 Million Patients 50K doctors by 2030	1.4 Mn+ Patients 38,900+ doctors
 Social Impact	Livelihood: 2.5 million beneficiaries Lives: 500,000 beneficiaries	414,144 beneficiaries

Key Highlights for Q3 FY26



Double '**A**' Rating in Climate Change and Water Security. Positioning Lupin as a leader in corporate transparency and actions on environment.



Secured 91 / 100 in S&P Global ESG Rating for 2025. Cementing Global No.1 ranking in the pharma industry³.



The Science Based Targets initiative (SBTi) has formally approved Lupin's greenhouse gas (GHG) emissions reduction goals.



4 sites progressing towards Zero Waste to Landfill certification, while 3 products on track for Anti-Microbial Resistance (AMR) certification.

Lupin ESG Framework and ESG Ratings



Our Purpose

We catalyze treatments that transform hope into healing

Our ESG Framework
Paving a sustainable future for Planet, People, and Patients



Planet

Catalyzing Planet Action

Climate Change

Water

Waste

Biodiversity



People

Transforming Our People

Diversity and Inclusion

Employee Volunteering

Employee Well-Being and Safety

Supplier Sustainability



Patients

Healing Patients

Product Launches and Quality

Patient Assistance Program

Education and Awareness

Diagnosis and Rehabilitation

ESG Ratings Update

Sustainability Ratings

S&P Global

91/100 in 2025 S&P Global ESG Rating.
(17/100 in 2021)

No. 1 in Pharma Sector

Sustainability Yearbook Member

2nd Consecutive year in S&P Global Yearbook 2025

SUSTAINALYTICS

25.2 Medium Risk in 2025.
decreasing ESG Risk rating (42.69 Severe Risk in 2019)



'A' leadership rating in Climate & Water in 2025 (F in 2021)

MSCI

Upgraded 'BBB' ESG rating in 2025 (BB in 2024)



71/100 ESG rating score for FY2025

Our Sustainability Efforts are aligned to Global Frameworks, Certifications & Standards



ecovadis

S&P Global



SUSTAINALYTICS




United Nations Global Compact



Taskforce on Nature-related Financial Disclosures



- Lupin placed among the Top 10% of companies in our industry based on S&P Global CSA score for 2024. Earns a spot in the esteemed S&P Global Sustainability Yearbook again
- Lupin Secures SBTi Validation for Emission Reduction Targets
- Lupin Nagpur wins two Pharmaceutical Category Award and Change Maker Award at the 12th Global Nagpur Awards 2025
- Lupin Research Park facility (Pune) awarded the LEED Platinum certification – the first pharmaceutical company in India
- All 12 manufacturing sites, R&D Center and Corporate office in India, certified for ISO 14001 and ISO 45001
- Lupin won the “Sustainable Organization of the Year” Award at the 2nd edition of Net Zero Summit & Awards
- Lupin Diagnostics won Pathology Lab of the Year – Chain 2025 at FE Healthcare Summits & Awards
- Lupin enters the Asia Book of Records for maximum camps conducted on bone mineral density as part of its patient-centric initiative
- Mandideep facility honored with the Medal of Honor for environmental protection by the Hon’ble Chief Minister of Madhya Pradesh, Dr. Mohan Yadav, at the Annual Environment Awards
- HuMrahi, Lupin’s Patient Support Program, won the Excellence in Patient Support Program category at the 14th ELETs Healthcare Innovation Awards, the 11th edition of the India Pharma, and The Economic Times RE-Pharma Awards
- Pithampur team won seven prestigious awards in the Platinum, Gold, and Silver categories at the CII National Level 5S competition
- LupinLife, Lupin’s consumer healthcare arm, won the Best Impact Creator in Healthcare category at the Big Impact Awards 2025 organized by Big FM 92.7
- Tarapur team won the Gold Award at the India Green Manufacturing Challenge (IGMC)
- Lupin Tarapur won the Excellence in Digitization & Automation Award at the Future of Manufacturing Summit & Awards 2025
- Ankleshwar and CSN facilities won Gold Medals at 11th National Awards for Manufacturing Competitiveness (NAMC) 2024-25
- Lupin won the Best Green Procurement Initiative award at the 3rd NXTGEN ProcureConnect Confex & Awards 2024
- LHWRF won the Best Social Welfare Initiative of the Year award at the 13th Edition of CSR Summit & Awards 2025



Thank You